Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 10/20 | 0.47 |
| ▸ | HTR1D | P28221 | 10/20 | 0.47 |
| ▸ | HTR1B | P28222 | 10/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834196 | 0.94 | UTS2R (0.51) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4831867 | 0.93 | TSHR (0.51) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4834411 | 0.93 | UTS2R (0.49) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4832742 | 0.92 | UTS2R (0.49) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4825185 | 0.92 | UTS2R (0.48) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4832382 | 0.92 | MEN1 (0.49) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL14279461 | 0.90 | UTS2R (0.47) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4828135 | 0.90 | UTS2R (0.46) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL14279460 | 0.89 | UTS2R (0.46) | UTS2RADRA2ADRD2SLC6A2HTR2A | |
| SCHEMBL4831869 | 0.89 | UTS2R (0.59) | UTS2RADRA2ADRD2SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320989-B2 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS, INC. | 2008-01-03 | — | — | US | disclosed |
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054850-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | UTS2R 1/4885ADRA2A 200/4885DRD2 1127/4885 |
| US-20080004312-A1 | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists | UTS2R, GPR17, NTSR2 | UTS2R 1/4885ADRA2A 200/4885DRD2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.